Kirill Osipov commented on the recent invalidation of yet another patent of Russian generic producer Nativa

Pharmaceutical Bulletin – one of the largest professional magazines devoted to Russian pharma – published an article on the recent invalidation of yet another patent of Nativa. Nativa is a Russian generic producer, infamous for its involvement in numerous patent infringement cases with the largest originator makers. Nativa’s patent, rendered invalid in the end of January, was for invention claimed to be dependent on the substance patented by Bristol-Myers Squibb and used in the production of Sprycel.

The Head of Legal Department of ARS-Patent Kirill Osipov provided his comments to Pharmaceutical Bulletin on the case and the acute problem of dependent inventions in general.

The full article is available here.

Make an enquiry

Latest News

ARS-Patent writes about new domestic regulations intended to fight evergreening of pharmaceutical patents


Anna Pustogvar, patent expert at ARS-Patent, and Kirill Osipov, the Head of Legal Department of ARS-Patent, have been published in spring Newsletters ...

Read more
More about our presence in IP rankings


Last week IP STARS published results of their extensive annual research on IP firms with the focus on patent practice. ARS-Patent is pleased to remain...

Read more

View all our News


Meet us at BIO 2019 in Philadelphia


Meet Kirill Osipov, the Head of Legal Department at ARS-Patent, and Pavel Vorobev, patent attorney at ARS-Patent, at the BIO International Convention ...

Read more
Meet ARS-Patent at INTA 2019


On May 18-22, 2019, ARS-Patent will attend the annual meeting of International Trademark Association (INTA), which will take place in Boston, Massachu...

Read more

See all Events

Back top